Clinical trials: Seizure Disorder, Partial
Partial Onset Seizures, Epilepsy
A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older
The purpose of this study is to assess the safety of perampanel in the treatment of partial onset seizures in participants of age 12 years and older with epilepsy.
- Trial name
- NCT03836924
- Testing
- Perampanel
- Where
- 12 sites in India
- Volunteers
- 200 people
- Sponsor
- Eisai Pharmaceuticals India Pvt. Ltd
Seizures
Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures
This is a Phase IV adjunctive treatment dose-optimization study evaluating the efficacy, safety, and health outcomes of ezogabine/retigabine immediate release (IR) (GW582892) compared with placebo in adult subjects with…
- Trial name
- NCT01721317
- Testing
- Ezogabine/Retigabine IR
- Where
- 11 sites in United States, Greece
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Epilepsy
An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures
This is a multicentre, open label study to examine the effect of ezogabine/retigabine on the voiding function of adult subjects with drug-resistant partial onset seizures (POS).
- Trial name
- NCT01607346
- Testing
- ezogabine/retigabine
- Where
- 7 sites in United States, France and 1 more
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Partial Seizures
A Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Extension Study)
The purpose of this study is to assess the long-term safety and efficacy of zonisamide used as an adjunctive treatment in pediatric subjects treated with 1 or 2 other anti-epileptic drugs (AEDs).
- Trial name
- NCT01136954
- Testing
- Zonisamide
- Where
- Italy
- Volunteers
- 144 people
- Sponsor
- Eisai Limited
Infantile Spasms
Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy
The sponsor is developing a new paediatric formulation of vigabatrin to better adjust the dose to body weight and to limit waste of unused drug.
- Trial name
- SoluWest (NCT02220114)
- Testing
- Vigabatrin: Vigabatrin new ST formulation then Sabril®
- Where
- 12 sites in France
- Volunteers
- 38 people
- Sponsor
- Orphelia Pharma
Epilepsy, Partial
Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in Epilepsy
Patients with partial-onset seizures seen in community-based practices were to be included in this therapeutic use study to assess the safety and tolerability of Keppra (Levetiracetam) and to confirm the favorable safety of the…
- Trial name
- NCT00643500
- Testing
- Levetiracetam
- Volunteers
- 342 people
- Sponsor
- UCB Pharma
Primary Generalized Tonic-Clonic or Partial Onset Seizures, Lennox Gastaut Syndrome
An Extended Access Program (EAP) for Perampanel
The main objective of this EAP is to ensure that participants participating in Study E2007-G000-332, Study E2007-G000-311, E2007-G000-238, E2007-G000-338 or EAP E2007-G000-401 continue to have access to perampanel until such time…
- Trial name
- NCT02307578
- Testing
- Perampanel
- Where
- 27 sites in Belgium, Chile and 8 more
- Sponsor
- Eisai Inc.
Epilepsies, Partial
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo
Patients with partial seizures currently taking 1-3 antiepileptic medications will have a 50:50 chance to receive Lyrica 300 mg per day or placebo (no active ingredients) added on to their current medications for 3 months.
- Trial name
- NCT00351611
- Testing
- Lyrica (pregabalin)
- Where
- 150 sites in United States, Bulgaria and 7 more
- Volunteers
- 187 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Partial Epilepsy
A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year Olds
Primary objective: To evaluate the safety and tolerability of cenobamate in Japanese pediatric subjects 2-17 years of age with partial-onset (focal) seizures
- Trial name
- NCT07594158
- Testing
- Cenobamate (tablet) for 12 to < 18 year olds, Cenobamate (syrup) for 2 to < 18 year olds
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Epilepsy, Partial
Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy
The purpose of this study is to assess whether Lyrica is a safe and effective treatment for partial epilepsy in comparison with an established treatment, Lamictal.
- Trial name
- NCT00280059
- Testing
- Pregabalin, Lamotrigine
- Where
- 102 sites in Belgium, Bulgaria and 27 more
- Volunteers
- 660 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Epilepsy
Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
The purpose of this study was to evaluate the safety and tolerability of perampanel (up to 12 mg/day) given as adjunctive treatment in subjects with refractory partial seizures and to evaluate the maintenance of effect of…
- Trial name
- NCT00735397
- Testing
- perampanel
- Where
- 239 sites in United States, Argentina and 37 more
- Volunteers
- 1,218 people
- Sponsor
- Eisai Inc.
Drug Resistant Epilepsy, Epilepsy
A Pilot Study to Evaluate the Efficacy and Safety of NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy
This will be a prospective, pilot, open-label, two-arm, parallel-group, randomized study to evaluate the efficacy and safety of low-intensity focused ultrasound (LIFU) neuromodulation using NaviFUS System in patients with…
- Conditions
- Drug Resistant Epilepsy, Epilepsy, Epilepsy, Temporal Lobe, Seizures, Focal
- Trial name
- NCT06492720
- Testing
- Focused ultrasound (FUS) treatment
- Where
- Taiwan
- Volunteers
- 16 people
- Sponsor
- NaviFUS Corporation
Epilepsies, Partial
Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures
Subjects enrolled in the SP615, SP756, or SP774 open-label extension (OLE) trials receiving oral SPM 927 for at least 8 weeks and a stable dose of up to 3 antiepileptic medications may participate in a research trial at…
- Trial name
- NCT00151879
- Testing
- SPM 927
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- UCB Pharma
Epilepsy, Focal Epilepsy
Assessment of Patients With Drug-resistant Temporal Lobe Epilepsy With EEG Extended With Intra-auricular Electrodes
The study aims to evaluate the effectiveness of long-term video EEG monitoring using 10-20 electrodes extended with intra-auricular electrodes in locating the seizure onset zone and interictal epileptiform discharges (IEDs) in…
- Conditions
- Epilepsy, Focal Epilepsy, Drug Resistant Epilepsy
- Trial name
- NCT06366009
- Testing
- NaoX in-ear EEG system
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- Przemyslaw Kunert
Epilepsy, Epilepsies, Partial
A Study of the Efficacy and Safety of Topiramate in the Treatment of Patients With Difficult to Control Epilepsy
The purpose of the study is to evaluate the effectiveness and safety of topiramate as add-on therapy in patients with difficult to control partial onset seizures who are taking one or two standard anti-epileptic drugs.
- Conditions
- Epilepsy, Epilepsies, Partial, Seizures
- Trial name
- NCT00236730
- Testing
- topiramate
- Volunteers
- 178 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Focal Epilepsy
An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy
CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy.
- Trial name
- NCT07238868
- Testing
- CB03-154
- Where
- Australia
- Volunteers
- 144 people
- Sponsor
- Shanghai Zhimeng Biopharma, Inc.
Focal Onset Seizure, Focal Onset Epilepsy
Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures
This Phase 2, prospective, interventional, active extension study was designed to evaluate the long-term safety and tolerability of NBI-921352 as adjunctive therapy in adult participants with focal onset seizures who completed 11…
- Trial name
- NCT05493293
- Testing
- NBI-921352
- Where
- 26 sites in Australia, Belgium and 5 more
- Volunteers
- 82 people
- Sponsor
- Neurocrine Biosciences
Seizure Disorder, Partial
To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures
To evaluate the long-term safety and efficacy of pregabalin in patients with partial seizures.
- Trial name
- NCT00141388
- Testing
- Pregabalin
- Where
- 56 sites in United States, Canada
- Volunteers
- 455 people
- Sponsor
- Pfizer
Epilepsies, Partial
Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures
Evaluation of the safety and efficacy of Oxcarbazepine XR as adjunctive treatment for adults with partial onset seizures
- Trial name
- PROSPER1 (NCT00772603)
- Testing
- 2400mg SPN-804, 1200mg SPN-804
- Where
- 71 sites in United States, Bulgaria and 6 more
- Volunteers
- 366 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Seizures, Epilepsy
A Study of the Safety of Topiramate Given in Combination With Other Medications in Adults and Children With Seizures
The purpose of this observational study is to evaluate the safety of topiramate when used in combination with other medications for seizures in adults and children.
- Trial name
- NCT00297349
- Testing
- Topiramate
- Volunteers
- 153 people
- Sponsor
- Janssen Cilag Pharmaceutica S.A.C.I., Greece